<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0370121</journal-id>
<journal-id journal-id-type="pubmed-jr-id">6712</journal-id>
<journal-id journal-id-type="nlm-ta">Prog Neurobiol</journal-id>
<journal-id journal-id-type="iso-abbrev">Prog. Neurobiol.</journal-id>
<journal-title-group>
<journal-title>Progress in neurobiology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0301-0082</issn>
<issn pub-type="epub">1873-5118</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27519538</article-id>
<article-id pub-id-type="pmc">5362348</article-id>
<article-id pub-id-type="doi">10.1016/j.pneurobio.2016.07.004</article-id>
<article-id pub-id-type="manuscript">NIHMS810294</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>NEW DRUG DEVELOPMENTS IN PSYCHOSIS: CHALLENGES, OPPORTUNITIES AND STRATEGIES</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Keshavan</surname>
<given-names>Matcheri S.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">$</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lawler</surname>
<given-names>Ashley N.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nasrallah</surname>
<given-names>Henry A.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tandon</surname>
<given-names>Rajiv</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Psychiatry, Beth Israel Deaconess Medical Center and Massachusetts Mental Health Center, Harvard Medical School. Address: Address: room 610, MMHC 75 Fenwood Road, Boston MA 02115.</aff>
<aff id="A2"><label>2</label>Department of Neurology &amp; Psychiatry, St Louis University.</aff>
<aff id="A3"><label>3</label>Department of Psychiatry, University of Florida, Gainsville, Florida. and the North Florida/South Georgia Veteransâ€™ Administration Medical Center, Gainesville, FL 32610</aff>
<author-notes>
<corresp id="CR1"><label>$</label> Address for correspondence. Tel No: 617 754 1256; Address: room 610, MMHC Fax No: 617 754 1250 <email>mkeshava@bidmc.harvard.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>12</day>
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>09</day>
<month>8</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>5</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>5</month>
<year>2018</year>
</pub-date>
<volume>152</volume>
<fpage>3</fpage>
<lpage>20</lpage>
<!--elocation-id from pubmed: 10.1016/j.pneurobio.2016.07.004-->
<abstract>
<p id="P1">All currently approved drugs for schizophrenia work mainly by dopaminergic antagonism. While they are efficacious for psychotic symptoms, their efficacy is limited for negative symptoms and cognitive deficits which underlie the substantive disability in this illness. Recent insights into the biological basis of schizophrenia, especially in relation to non-dopaminergic mechanisms, have raised the efforts to find novel and effective drug targets, though with relatively little success thus far. Potential impediments to novel drug discovery include the continued use of symptom based disease definitions which leads to etiological and pathophysiological heterogeneity, lack of valid preclinical models for drug testing, and design limitations in clinical trials. These roadblocks can be addressed by (i) characterizing trans-diagnostic, translational pathophysiological dimensions as potential treatment targets, (ii) efficiency, accountability and , transparency in approaches to the clinical trials process, and (iii) leveraging recent advances in genetics and <italic>in vitro</italic> phenotypes. Accomplishing these goals is urgent given the significant unmet needs in the pharmacological treatment of schizophrenia. As this happens, it is imperative that clinicians employ optimal dosing, measurement-based care, and other best practices in utilizing existing treatments to optimize outcomes for their patients today.</p>
</abstract>
<kwd-group>
<kwd>Psychosis</kwd>
<kwd>schizophrenia</kwd>
<kwd>antipsychotics</kwd>
<kwd>glutamate</kwd>
<kwd>dopamine</kwd>
<kwd>clinical trials</kwd>
<kwd>efficacy</kwd>
<kwd>drug development</kwd>
<kwd>pharmacology</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>